Careprost and Blinq-I-Lash Lash Serums
Sun Pharma lists Careprost 0.03% bimatoprost eye drops in a 3ml pack. Altus describes Blinq-I-Lash as bimatoprost ophthalmic solution 0.03%; its store listing is for 3ml. The eMC lists bimatoprost and Lumigan eye drops as prescription-only medicines. Ask a GP, pharmacist or prescriber about the specific product before use. Speak to a GP, pharmacist or prescriber before using a bimatoprost eyelash product. Do not use during pregnancy unless your prescriber specifically advises it, and discuss eye-pressure treatment with them.
Careprost and Blinq-I-Lash product information
Sun Pharmaceutical Industries lists Careprost 0.03% bimatoprost eye drops. Altus Lifecare describes Blinq-I-Lash as bimatoprost ophthalmic solution 0.03%.
| Product | Description | Pack size |
|---|---|---|
| Careprost | Sun Pharma lists 0.03% bimatoprost eye drops. | The store lists one 3ml bottle as about two months of nightly use, or three 3ml bottles as about six months. Follow the leaflet in the pack and your prescriber's directions. |
| Blinq-I-Lash | Altus describes bimatoprost ophthalmic solution 0.03%. | The store lists a 3ml bottle. |
Ask a GP, pharmacist or prescriber about the specific product before use.
How the LATISSE label describes lash application
The US FDA-approved LATISSE label describes instructions for eyelash hypotrichosis. It directs users to apply once nightly to the skin of the upper eyelid margin at the base of the lashes with a supplied sterile, disposable applicator, using a fresh applicator for each eye. Blot any excess and do not apply along the lower lash line.
For LATISSE, contact lenses should be removed before use and may be put back in after 15 minutes. The LATISSE label is specific to this US product; ask a prescriber about application instructions for other products.
Bimatoprost safety information
The LATISSE label reports increased brown iris pigmentation that is likely to be permanent. It also notes darkening of the skin around the eye and warns that repeated contact with other skin can cause hair growth outside the intended area. The NHS advises avoiding repeated contact between bimatoprost solution and skin.
The LATISSE label also warns that use alongside Lumigan or other prostaglandin medicines used to lower intraocular pressure may interfere with the intended pressure reduction. If you use treatment for eye pressure, discuss bimatoprost with your prescriber before use. The label says there are no adequate, well-controlled studies in pregnant women. Do not use during pregnancy unless your prescriber specifically advises it.
For more detail, read the bimatoprost lash product safety guide.
UK prescription status and advice
The eMC lists bimatoprost 0.3mg/ml eye drops and Lumigan eye drops as prescription-only medicines. Ask a GP, pharmacist or prescriber about the specific product, especially if you are pregnant or use eye-pressure treatment.
Frequently asked questions
Is bimatoprost prescription-only in the UK?
The eMC lists bimatoprost and Lumigan eye drops as prescription-only medicines. Ask a GP, pharmacist or prescriber about the specific Careprost or Blinq-I-Lash product.
What does the LATISSE label say about application?
The US LATISSE label describes once-nightly application to the upper eyelid margin with a sterile, disposable applicator, using a fresh applicator for each eye. Remove contact lenses first; they may be reinserted after 15 minutes. These instructions are specific to LATISSE.
Does the US LATISSE label warn about eye-pressure treatment?
Yes. It says using LATISSE with Lumigan or another prostaglandin analogue used to lower intraocular pressure may interfere with the intended pressure reduction. Ask a prescriber about your treatment.